A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis

计划入组 207 人 · 首次发布于 2018 年 6 月 26 日

MOR and COMT SNP Polymorphism and Pain

计划入组 100 人 · 首次发布于 2008 年 10 月 16 日

Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma

计划入组 28 人 · 首次发布于 2026 年 6 月 8 日

MOR-105

MOR-102

MOR-8457

MorphoSys

Germany

JOHN D ARCHBOLD MEMORIAL HOSPITAL

United States

MORPHOTEK

United States

Morari Launches FDA-Cleared Neurostimulation Patch for Men's Sexual Wellness in Twin Cities

FDA Clears Novel Electronic Patch for Premature Ejaculation Treatment

Chemomab Announces Positive CM-101 Phase 2 Trial Results and Outlines Phase 3 Plans for Primary Sclerosing Cholangitis